Management of High-Risk Relapsed/Refractory Pediatric Neuroblastoma: Novel Agents and Patient Perspectives for Advanced Practitioners

Target Audience
The educational design of this activity addresses the needs of pediatric oncology nurses, advanced practice providers (including nurse practitioners and physician assistants), pediatric oncologists, social workers, and other members of the team caring for children with pediatric neuroblastoma.

Statement of Need/Program Overview
Advanced practitioners have a vital role to play in the care of neuroblastoma, The most common extracranial solid tumor in childhood, with about 700 new cases in the US each year among children 14 and younger. Ad Immunotherapy promises to address a number of unmet therapeutic needs and improve the prognosis for patients with relapsed/refractory high-risk neuroblastoma.

Join a multidisciplinary panel of experts and patient advocates led by Dr. Shakeel Modak as they discuss emerging treatment options, including anti-GD2 agents, for high-risk relapsed/refractory pediatric neuroblastoma. Panelists will also review the determination of risk status, patient-selection criteria, and strategies to address adverse effects throughout the course of treatment. Learn strategies to educate and improve communication with patients, families, and caregivers from a patient advocate and parent on the panel to ensure greater care coordination.

Learning Objectives
After completing this activity, the participant should be better able to:

Summarize the mechanisms of action of emerging agents for relapsed/refractory high-risk neuroblastoma
Describe strategies to manage challenges of administration and treatment-related adverse effects in patients undergoing treatment for relapsed/refractory high-risk neuroblastoma
Facilitate communication with patients, caregivers, and families in navigating treatment options, side-effect management, and care coordination